Prochlorperazine Edisylate and Timolol eent

• Generic Name: prochlorperazine
• Dosage Forms: n.a.
• Other Brand Names: Compazine, Compro

Symptomatic management of psychotic disorders (i.e., schizophrenia).

Short-term management of nonpsychotic anxiety.

Efficacy established in patients with generalized anxiety disorder; not established whether prochlorperazine is useful for the management of other nonpsychotic conditions in which anxiety or manifestations that mimic anxiety are evident (e.g., physical illness, organic mental conditions, agitated depression, character pathologies).

Because of the risks of toxicity, use only as an alternative to other less toxic anxiolytic agents (e.g., benzodiazepines) in most patients.

Management of severe nausea and vomiting of various etiologies (e.g., postoperative, acute migraine, toxins, radiation, or cytotoxic drugs).

Not effective in preventing vertigo or motion sickness, or for the management of emesis caused by the action of drugs on the nodose ganglion or locally on the GI tract.

Use not recommended for the prevention and treatment of nausea and vomiting associated with pregnancy except in cases of severe nausea and vomiting so serious and intractable that pharmacologic intervention is required and the potential benefits justify the possible risks to the fetus. (See Fetal/Neonatal Morbidity under Cautions.)

Has not been shown to be effective for the management of behavioral complications in patients with mental retardation.

• Generic Name: timolol ophthalmic
• Dosage Forms: n.a.
• Other Brand Names: Betimol, Istalol, Timoptic Ocudose, Timoptic Ocumeter, Timoptic Ocumeter Plus, Timoptic-XE, Timoptic

Reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension. Used alone or in conjunction with another IOP-lowering drug (e.g., latanoprost, a carbonic anhydrase inhibitor).

Fixed-combination preparation containing timolol maleate and dorzolamide hydrochloride used to reduce elevated IOP in patients with open-angle glaucoma or ocular hypertension who have not responded adequately (i.e., failed to achieve target IOP as determined after multiple measurements over time) to a topical β-adrenergic blocking agent.

Fixed-combination preparation associated with slightly smaller decrease in IOP than combination therapy with timolol (administered twice daily) and dorzolamide (administered 3 times daily).